| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $14.1M | — | -12.6% |
| SG&A Expense | $7.9M | — | -12.7% |
| Operating Income | -$21.9M | — | +12.4% |
| Net Income | -$19.7M | — | +0.1% |
| EPS (Basic) | -$0.28 | — | +45.1% |
| EPS (Diluted) | -$0.28 | — | +45.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $26.3M | -40.7% | -34.2% |
| Short-term Investments | $11.4M | -19.9% | -59.9% |
| Current Assets | $39.4M | -35.5% | -45.1% |
| Total Assets | $49.8M | -33.0% | -43.0% |
| Current Liabilities | $37.9M | -13.2% | +38.8% |
| Total Liabilities | $43.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.6M | — | +19.7% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $2.6M | — | +5193.1% |
| Financing Cash Flow | $954K | — | -7.2% |
| Free Cash Flow | -$21.6M | — | +19.8% |
| +21.3% |
| Stockholders' Equity | $6.1M | -74.8% | -88.2% |